Join our daily newsletter At The Bell to receive exclusive market insights
- Noxopharm (NOX) is developing a new mRNA “vaccine enhancer” product to improve the effectiveness of vaccines and reduce inflammation
- The company says it has selected a lead candidate for further development, and the product — dubbed SOF-VAC — will be part of its Sofra preclinical platform
- NOX says SOF-VAC is the smallest known molecule of its type to have demonstrated “strong activity” against inflammation
- Noxophram is developing the product in partnership with the Hudson Institute of Medical Research
- Shares in Noxopharm are up 3.16 per cent to 9.8 cents at midday AEDT
Biotech company Noxopharm (NOX) has created an mRNA “vaccine enhancer” to improve the effectiveness of vaccines and reduce inflammation.
The company on Tuesday said it had selected a lead candidate for further development, and the new product — dubbed SOF-VAC — will be part of its Sofra preclinical platform.
Noxophram is developing the vaccine enhancer product in partnership with the Hudson Institute of Medical Research.
The company said it aimed to make a broad range of mRNA vaccines safer by reducing the adverse effects of inflammation, which would provide the basis for the development of a pipeline of new proprietary drugs.
The team’s recent development work on SOF-VAC has shown strong in vitro and in vivo activity against inflammation, with the product representing a first-in-class achievement as the smallest known molecule of its type to have demonstrated this activity.
Noxopharm CEO Gisela Mautner said mRNA vaccines represented one of the “most exciting and rapidly developing areas of medicine” today.
“They are expected to play an even greater role in the years ahead as they become applicable to numerous diseases and we believe SOF-VAC could contribute significantly in this field,” Ds Mautner said.
“Our collaboration with the Hudson Institute team is delivering promising results in the lab, and we aim to build on those and generate interest in our assets.”
NOX said on top of its enhancing effect, the SOF-VAC technology had the potential to support more cost-effective mRNA vaccine manufacturing.
Shares in Noxopharm were up 3.16 per cent to 9.8 cents at midday AEDT.
